title: American Cancer Society guideline for the early detection of prostate cancer: update 2010.
abstract: In 2009, the American Cancer Society (ACS) Prostate Cancer Advisory Committee began the process of a complete update of recommendations for early prostate cancer detection. A series of systematic evidence reviews was conducted focusing on evidence related to the early detection of prostate cancer, test performance, harms of therapy for localized prostate cancer, and shared and informed decision making in prostate cancer screening. The results of the systematic reviews were evaluated by the ACS Prostate Cancer Advisory Committee, and deliberations about the evidence occurred at committee meetings and during conference calls. On the basis of the evidence and a consensus process, the Prostate Cancer Advisory Committee developed the guideline, and a writing committee drafted a guideline document that was circulated to the entire committee for review and revision. The document was then circulated to peer reviewers for feedback, and finally to the ACS Mission Outcomes Committee and the ACS Board of Directors for approval. The ACS recommends that asymptomatic men who have at least a 10-year life expectancy have an opportunity to make an informed decision with their health care provider about screening for prostate cancer after they receive information about the uncertainties, risks, and potential benefits associated with prostate cancer screening. Prostate cancer screening should not occur without an informed decision-making process. Men at average risk should receive this information beginning at age 50 years. Men in higher risk groups should receive this information before age 50 years. Men should either receive this information directly from their health care providers or be referred to reliable and culturally appropriate sources. Patient decision aids are helpful in preparing men to make a decision whether to be tested.
authors.affiliation: University of Virginia School of Medicine, Charlottesville, VA, USA.
authors.forename: Andrew M D
authors.initials: AM
authors.lastname: Wolf
authors.forename: Richard C
authors.initials: RC
authors.lastname: Wender
authors.forename: Ruth B
authors.initials: RB
authors.lastname: Etzioni
authors.forename: Ian M
authors.initials: IM
authors.lastname: Thompson
authors.forename: Anthony V
authors.initials: AV
authors.lastname: D'Amico
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Volk
authors.forename: Durado D
authors.initials: DD
authors.lastname: Brooks
authors.forename: Chiranjeev
authors.initials: C
authors.lastname: Dash
authors.forename: Idris
authors.initials: I
authors.lastname: Guessous
authors.forename: Kimberly
authors.initials: K
authors.lastname: Andrews
authors.forename: Carol
authors.initials: C
authors.lastname: DeSantis
authors.forename: Robert A
authors.initials: RA
authors.lastname: Smith
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D001007:Anxiety; D044963:Biopsy, Fine-Needle / Q000009:adverse effects; D003266:Continuity of Patient Care; D003657:Decision Making; D055088:Early Detection of Cancer / Q000592:standards*; D019317:Evidence-Based Medicine; D006801:Humans; D008017:Life Expectancy; D008297:Male; D008403:Mass Screening / Q000592:standards*; D018962:Phlebotomy / Q000009:adverse effects; D010808:Physical Examination / Q000379:methods; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000009:adverse effects / Q000379:methods; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy; D011878:Radiotherapy / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D012007:Rectum; D012016:Reference Values; D018570:Risk Assessment; D012307:Risk Factors; D018426:SEER Program; D012735:Sexual Dysfunction, Physiological / Q000209:etiology; D014481:United States / Q000453:epidemiology; D014550:Urinary Incontinence, Stress / Q000209:etiology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen